Oxycodone/naltrexone - Pfizer

Drug Profile

Oxycodone/naltrexone - Pfizer

Alternative Names: ALO-02; Naltrexone/oxycodone - Pfizer; Oxycodone-naltrexone core (King); TROXYCAER

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Analgesics; Cyclopropanes; Drug withdrawal therapies; Morphinans; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pain(In volunteers) in USA (IV, Injection)
  • 18 Oct 2016 Launched for Pain (Abuse-resistant) in USA (PO) before October 2017 (Martindale/Pfizer website, November 2017)
  • 19 Aug 2016 Registered for Pain (Abuse-resistant) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top